Healthcare Costs of the Combination of Metformin/Dipeptidyl Peptidase-4 Inhibitors Compared with Metformin/Other Oral Antidiabetes Agents in Patients with Type 2 Diabetes and Metabolic Syndrome
Diabetes Technology & Therapeutics , Vol. 0, No. 0.
Source: Diabetes Technology - Category: Endocrinology Tags: article Source Type: research
More News: Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Healthcare Costs | Metabolic Syndrome | Metformin